| Amiodarone |
75.2 ± 12.9, 92.0 ± 5.5, 0.8, 95.1 ± 10.1 ,69.1 ± 24.1, 1.3 |
4hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| Amitriptyline |
70.9 ± 16.8, 72.0 ± 5.3, 1, 68.1 ± 9.1, 67.0 ± 11.6, 1 |
4hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| Chlorpromazine |
36.6 ± 19.4, 48.4 ± 11.9, 0.8, 17.3 ± 7.6, 25.3 ± 10.8, 0.7 |
4hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| Fluoxetine |
63.4 ± 8.1, 43.1 ± 9.6 ,1.5, 58.0 ± 15.1, 63.3 ± 26.2, 0.9 |
4hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| Idarubicin |
7.9 ± 3.3 , 4.2 ± 2.0, 1.9, 11.5 ± 5.7 ,6.2 ± 4.0, 1.9 |
4hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| imipramine |
91.6 ± 18.2, 84.1 ± 10.3, 1.1, 71.4 ± 22.4, 90.3 ± 11.7, 0.8 |
4hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| mefloquine |
2.9 ± 1.1, 2.3 ± 1.0, 1.4 ,3.4 ± 1.3, 3.6 ± 2.2, 1.2 |
4hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| Menadione |
18.0 ± 7.2, 14.7 ± 7.9 ,1.2, 19.5 ± 8.3, 14.0 ± 8.7, 1.4 |
4hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| Nortriptyline |
62.0 ± 18.7, 57.8 ± 28.3, 1.1, 65.3 ± 25.0, 49.2 ± 23.0, 1.3 |
4hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| paroxetine |
37.5 ± 15.9, 36.9 ± 27.9, 1, 37.1 ± 11.3, 32.3 ± 17.8, 1.2 |
4hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| sertraline |
30.7 ± 4.7, 24.7 ± 16.0, 1.2, 29.1 ± 12.0, 23.6 ± 19.2, 1.2 |
4hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| Tamoxifen |
97.9 ± 28.0, 64.4 ± 11.4, 1.5, 75.2 ± 8.4, 43.9 ± 7.8, 1.7 |
4hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| Thioridazine |
31.0 ± 5.9, 27.7 ± 19.8 ,1.4, 24.4 ± 5.7, 21.9 ± 18.0, 1.6 |
4hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| Flutamide |
300.0 ± 0, 78.3 ± 24.8, 4.1, 266 ± 58.9 , 62.6 ± 27.3, 5 |
24hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| Nilutamide |
250 ± 86.6, 44.0 ± 12.0 , 5.7 , 300.0 ± 0, 15.6 ± 9.9 , 19.2 |
24hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| Troglitazone |
300.00 ± 0 , 1.4 ± 0.1, 219.8, 300.0 ± 0, 1.9 ± 0.1, 156.7 |
24hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| zoniporide |
300.00 ± 0, 22.1 ± 14.3, 13.6, 300.0 ± 0, 21.6 ± 5.1, 13.9 |
24hr |
|
H9c2 cells |
high-glucose–galactose cell viability assay with JC-1 mitochondrial membrane potential and ATP-depletion assays (CellTiter-Glo reagent ). |
|
Positive |
glucose/galactose IC50 ratio (JC-1 IC50 in glucose, JC-1 IC50 in galactose, JC-1 glu/gla, ATP IC50 in glucose, ATP IC50 in galactose, ATP glu/gla ) |
50 |
| Antimycin A |
5.9 (42.1nM/7.1nM) |
24hr |
|
L6 |
ATP levels in high-glucose (25 mM) or galactose (10 mM) medium |
|
Positive |
glucose/galactose IC50 ratio |
325 |
| Antimycin A |
10.7 (176.5nM/16.5nM) |
24hr |
|
H9c2 |
ATP levels in high-glucose (25 mM) or galactose (10 mM) medium |
|
Positive |
glucose/galactose IC50 ratio |
325 |
| Antimycin A |
17.7(58.1nM/3.3nM) |
24hr |
|
HepG2 |
ATP levels in high-glucose (25 mM) or galactose (10 mM) medium |
|
Positive |
glucose/galactose IC50 ratio |
325 |
| 1-Octylguanidine |
4.3 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| 3-NPA |
|
|
|
permeabilized LUHMES cells |
Assessment of the function of individual mitochondrial complexes using Agilent Seahorse XFe24 |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Antimycin A |
12000 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| azoxystrobin |
3.6 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Berberine |
7 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Carboxin |
3.1 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Deguelin |
450 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| fenamidone |
16 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| fenazaquin |
450 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Fenpyroximate |
5600 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Methyltriphenylphosphonium bromide |
8.6 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| MPP |
30 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Nefazodone |
10 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Oligomycin |
8.7 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Phenformin |
27 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| picoxystrobin |
50µM |
|
|
permeabilized LUHMES cells |
Assessment of the function of individual mitochondrial complexes using Agilent Seahorse XFe24 |
|
Positive |
|
326 |
| pyraclostrobin |
50µM |
|
|
permeabilized LUHMES cells |
Assessment of the function of individual mitochondrial complexes using Agilent Seahorse XFe24 |
|
Positive |
|
326 |
| Pyridaben |
75000 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Pyrimidifen |
10000 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Rotenone |
51 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Salinomycin |
3.7 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Sodium Azide |
11 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Cyanide |
5.2 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Tebufenpyrad |
2700 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
|
Positive |
EC25(NA) [Glc/Gal] |
326 |
| Cadmium |
4 |
4hr |
|
HPNE cell (human pancreatic Nestin-expressing cells) |
Mitochondrial toxicity: exposure to various concentrations of CdCl2 in the presence of 25 mM glucose or 10 mM galactose, followed by MTT assay |
increase |
Positive |
IC50_glucose/IC50_galactose |
334 |
